Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 2, 2016, Pages 532-539

  Pabreja, Swati ^a   Garg, Tarun ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Immune response; Immunostimulating complex; Mucosal vaccine; Quil A; Reverse phase evaporation

Indexed keywords

BACTERIOLOGY; IMMUNE SYSTEM; TUBES (COMPONENTS);

BACILLUS CALMETTE GUERIN; IMMUNE RESPONSE; IMMUNOSTIMULATING; MUCOSAL VACCINE; MYCOBACTERIUM TUBERCULOSIS; PULMONARY IMMUNIZATION; RESEARCH STUDIES; REVERSE PHASE;

VACCINES;

ANTIGEN; ANTIGEN 85 COMPLEX; BCG VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; ISCOM; LIPID; NANOCARRIER; QUIL A; SAPONIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85A, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; DRUG CARRIER; IMMUNOGLOBULIN CLASS; NANOMATERIAL;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; BCG VACCINATION; CACO 2 CELL LINE; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; HELPER CELL; HEMOLYSIS; HYDROPHOBICITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOCILIARY CLEARANCE; MUCOSA CELL; NONHUMAN; PARTICLE SIZE; PH; STATIC ELECTRICITY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; TUBERCULOSIS; VISCOSITY; ZETA POTENTIAL; ANIMAL; BLOOD; CACO-2 CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RELEASE; HUMAN; IMMUNOLOGY; MUCOSA; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; TUBERCULOSIS, PULMONARY; VACCINATION;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; CACO-2 CELLS; CELL SURVIVAL; DRUG CARRIERS; DRUG LIBERATION; FEMALE; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN ISOTYPES; ISCOMS; MICE; MUCOUS MEMBRANE; MYCOBACTERIUM TUBERCULOSIS; NANOSTRUCTURES; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84964355830     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.966195     Document Type: Article

References (29)

1. Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, et al 2013. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8 + T cells. J Immunol. 191:2514-2525.
2. Chaudhary S, Garg T, Murthy RS, Rath G, Goyal AK 2014. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target. 1-12.
3. Chol C, Guy C, Jacquet A, Castot-Villepelet A, Kreft-Jais C, Cambazard F, et al 2013. Complications of BCG vaccine SSI® recent story and risk management plan: the French experience. Pharmacoepidemiol Drug Saf. 22:359-364.
4. Collins SL, Chan-Li Y, Hallowell RW, Powell JD, Horton MR 2012. Pulmonary vaccination as a novel treatment for lung fibrosis. PLoS One. 7:e31299.
5. Cruz-Bustos T, Gonzalez-Gonzalez G, Morales-Sanfrutos J, Megia-Fernandez A, Santoyo-Gonzalez F, Osuna A. 2012. Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy. Int J Nanomed. 7:5941-5956.
6. Gagandeep Garg T., Malik B, Rath G, Goyal AK 2014. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 53:10-16.
7. Garg T. 2014. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 1-8.
8. Garg T, Goyal AK 2012. Iontophoresis: Drug delivery system by applying an electrical potential across the skin. Drug Deliv Lette. 2:270-280.
9. Garg T, Goyal AK 2014a. Biomaterial-based scaffolds-current status and future directions. Expert Opin Drug Deliv. 11:767-789.
10. Garg T, Goyal AK 2014b. Liposomes: Targeted and controlled delivery system. Drug Deliv Lett. 4:62-71.
11. Garg T, Goyal AK, Arora S, Murthy R. 2012a. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of Type-2 diabetes mellitus. Drug Deliv Lett. 2:251-261.
12. Garg T, Rath G, Goyal AK 2014. Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease-psoriasis. Crit Rev Ther Drug Carrier Syst. 31:331-364.
13. Garg T, Singh O, Arora S, Murthy R. 2012b. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 29:1-63.
14. Goyal AK, Rath G, Garg T. 2013a. Nanotechnological approaches for genetic immunization. In: Erdmann VA & Barciszewski J, Eds. DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases Berlin: Springer, pp. 67-120.
15. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK 2013b. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv.
16. Granfors K. 1979. Measurement of immunoglobulin M (IgM), IgG, and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease. J Clin Microbiol. 9:336-341.
17. Kaur M, Garg T, Rath G, Goyal AK 2014a. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 31:49-88.
18. Kaur M, Malik B, Garg T, Rath G, Goyal AK 2014b. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv.
19. Kaur R, Garg T, Das Gupta U., Gupta P, Rath G, Goyal AK 2014c. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol. 1-6.
20. Kirby DJ, Rosenkrands I, Agger EM, Andersen P, Coombes AG, Perrie Y. 2008. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target. 16:282-293.
21. Ko YT, Bickel U. 2012. Liposome-encapsulated polyethylenimine/oligonucleotide polyplexes prepared by reverse-phase evaporation technique. AAPS PharmSciTech. 13:373-378.
22. Modgill V, Garg T, Goyal AK, Rath G. 2014. Permeability study of ciprofloxacin from ultra-thin nanofibrous film through various mucosal membranes. Artif Cells Nanomed Biotechnol. 1-6.
23. Morie A, Garg T, Goyal AK, Rath G. 2014. Nanofibers as novel drug carrier - An overview. Artif Cells Nanomed Biotechnol. 1-9.
24. Oda K, Matsuda H, Murakami T, Katayama S, Ohgitani T, Yoshikawa M. 2000. Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants. Biol Chem. 381:67-74.
25. Orme IM. 2013. Vaccine development for tuberculosis: current progress. Drugs. 73:1015-1024.
26. Parnami N, Garg T, Rath G, Goyal AK 2013. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol.
27. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. 2014. Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol.
28. Sylvester PW. 2011. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol. 716:157-168.
29. Tang X, Deng W, Xie J. 2012. Novel insights into Mycobacterium antigen Ag85 biology and implications in countermeasures for M. tuberculosis. Crit Rev Eukaryot Gene Expr. 22:179-187.